Mustang Bio, Inc.

141 articles about Mustang Bio, Inc.

• Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

  3/28/2024

  Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy.

• Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

  3/11/2024

  Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

• Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

  3/7/2024

  Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma.

• Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

  1/11/2024

  Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference.

• Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

  12/11/2023

  Mustang Bio, Inc. today announced updated encouraging safety and efficacy data from Mustang’s multicenter Phase 1/2 clinical trial of MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”).

• Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

  11/14/2023

  Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.

• Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

  11/2/2023

  Mustang Bio, Inc. announced that interim Phase 1/2 data from Mustang’s multicenter clinical trial of MB-106, a CD20-targeted, autologous CAR-T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, have been selected for a poster presentation at the 65th American Society of Hematology Annual Meeting, taking place December 9-12, 2023 in San Diego.

• Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  10/30/2023

  Mustang Bio, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the purchase and sale of 2,588,236 of its shares of common stock at a purchase price of $1.70 per share.

• Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

  10/26/2023

  Mustang Bio, Inc. announced that the U.S. Food and Drug Administration has accepted the Company’s Investigational New Drug application of MB-109 for the treatment of recurrent glioblastoma and high-grade astrocytoma.

• Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  10/26/2023

  Mustang Bio, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,588,236 of its shares of common stock at a purchase price of $1.70 per share in a registered direct offering priced at-the-market under Nasdaq rules.

• Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

  9/7/2023

  Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.

• Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

  8/16/2023

  Mustang Bio, Inc. today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia

• Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

  8/14/2023

  Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.

• Mustang Bio to Participate in Two August 2023 Investor Conferences

  8/3/2023

  Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two investor conferences in August 2023.

• Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

  7/31/2023

  Mustang Bio, Inc. today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc.

• Mustang Bio Announces Participation in Upcoming Scientific Meetings - July 06, 2023

  7/6/2023

  Mustang Bio, Inc. announced that members of its management team will participate in the 2ndIn Vivo Engineering of Therapeutic Cells Summit, scheduled to take place from July 10-12, 2023, and the 8th Annual CAR-TCR Summit, scheduled to take place from August 29 – September 1, 2023, both in Boston, MA.

• Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

  6/15/2023

  Mustang Bio, Inc. announced that final data from the follicular lymphoma cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response and complete response rates and CAR T persistence in FL patients.

• Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

  6/12/2023

  Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer.

• Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

  5/18/2023

  uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support MB-106 and future pipeline.

• Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

  5/12/2023

  Mustang Bio, Inc. announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.